TherapeuticsMD(US:TXMD)2021-05-12 20:31Financial Performance - Total net product revenue increased by 60% in 1Q21 compared to 1Q20[11] - ANNOVERA net revenue increased by 285%[11] - BIJUVA net revenue increased by 120%[11] - The company reduced debt to $184 million by a $50 million cash payment[14] - Operating expenses were reduced by $16 million to $44.5 million compared to 1Q20[14] - Gross margin was 76%, impacted by $0.9 million in write-offs of production-related costs for ANNOVERA[14] ANNOVERA Performance and Strategy - ANNOVERA total prescriptions (TRx) grew by 164% year-over-year and 5% quarter-over-quarter in 1Q21[19] - Net revenue per unit for ANNOVERA was $1,071 in 1Q21, with an expected annual average of ~$1,100[11, 19] - The number of prescribers for ANNOVERA increased by approximately 17% in 1Q21 compared to 4Q20, from ~2,700 to ~3,160[19] IMVEXXY Performance - IMVEXXY net revenue increased by 10%[11] - Net revenue per unit improved to $61[11]